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Abstract 
Pathogenic bacteria are an important cause of high mortality rates and high healthcare 
costs in developing countries. The emergence of resistant species has made the 
development of new antimicrobial drugs necessary. A first approach to this issue is to 
understand how bacteria evolve their resistance mechanisms.  
On this basis, we performed adaptive evolution experiments of the ESKAPE 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baimannii, Pseudomonas aeruginosa and Enterobacter cloacae) 
organisms using a suite of five antibiotics. The results showed that resistance 
adaptation is a complex phenomenon that affects major phenotypical features such as 
the growth rate, which is mainly slowed down. Collateral sensitivity and resistance 
experiments revealed that adaptation resulted in cross-resistance across different 
classes of antibiotics in the majority of the cases showing that the mechanisms of 
resistance are not unique for each drug. 
The data and the knowledge gathered from the work done in this thesis can be used 
as a guiding tool during sequence analysis of the adapted strains. We expect that our 
final findings will shed light on the genetic responses of the ESKAPE pathogens 
exposed to antimicrobials. 
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Introduction 
History of Bacterial Diseases 
Bacteria were discovered in the late 1670s by Antonie van Leeuwenhoek, a Dutch 
cloth merchant who was an expert at lens grinding so that he could examine the weave 
of cloth. He observed bacteria for the first time in an unnatural water environment, 
pepper water1. Two more centuries were needed until it was proven that bacteria could 
cause disease. This proof was obtained from several scientists, but the most crucial 
evidence came from the work of Louis Pasteur and Robert Koch in the 1860s and the 
1870s. Pasteur showed that bacteria could not grow in sealed broth if the broth was 
boiled first. In 1890 Koch published his four criteria for establishing a relationship 
between the presence of a bacteria and a disease, after his discovery of anthrax 
bacillus and tubercle bacillus, the causative agents of anthrax and the tuberculosis 
disease, respectively2.  
However the deadly power of bacteria was known to humans long before their 
discovery. There are records of infectious diseases even in B.C.E. In 430 B.C.E the 
plague of Athens killed 20% of the Athenian troops that were fighting in the Great 
Peloponnesian War. In 2005 a correlation was made between DNA extracted from 
dental pulp of three teeth recovered from Kerameikos cemetery in Athens and a known 
pathogen. The scientists identified nucleotide sequences from a pathogenic bacterium, 
Salmonella Enterica Serovar Typhi, which causes typhoid fever3. The Plague of 
Justinian (541 to 750 A.D),  which eliminated one quarter to one half of the human 
population in the Eastern Mediterranean region, was likely a bubonic plague. 
Discovery and Production of Antibacterial Agents 
The inference that bacteria cause diseases led many researchers to start searching 
for ways to confront the problem. The 20th century is the era of the discovery and 
evolution of antimicrobial compounds. In 1909 Paul Ehrlich, a German physician, 
discovered the active compound 606, which was toxic against Treponema pallidum, a 
bacteria that causes syphilis4. A landmark in the history of medicine is 1932, when 
Bayer chemists, Josef Klarer and Fritz Mietzsch, first synthesized 
sulfoaminochrysoidine as part of a research program designed to find compounds that 
might act as antibacterial drugs in the body. In the late autumn 1932, Gerhard Domagk 
tested sulfoaminochrysoidïne in mice and found the drug effective against some 
important bacterial infections. In 1935 the drug was released in the market under the 
name Prontosil and Gerhard Domagk received the Nobel Prize in Medicine in 19392. 
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A year later Howard Florey and his team in Oxford devised a method for mass 
producing penicillin, the great discovery of Alexander Fleming in 1928. Florey and 
Ernst Boris Chain discovered penicillin’s therapeutic action and its chemical 
composition, which was confirmed by X-Ray Crystallography done by Dorothy 
Hodgkin. For their research in penicillin Chain, Florey and Fleming received the Nobel 
Prize in Medicine in 19455, 6. In the following 30 years several screening projects were 
carried out and a large number of antibacterial agents were introduced into the market 
(Figure 1). 
 
 
Figure 1: Timeline of classes of antibacterial agents introduced in the markets
7 
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Antibiotic Resistance 
After the 1950s the global availability of antibiotics increased abruptly. The 
uncontrolled sales of antibiotics and therefore the widespread use of them caused the 
emergence and spread of pathogenic bacteria resistant to many antibiotics. In addition 
to that, only two new classes of antibiotics of novel mechanisms of action (linezolid 
and daptomycin) have been introduced into the market during the last three decades 
which led to the continuous use of the same antibiotic classes for the last 40-50 years.  
Today infectious diseases still remain the main cause of human deaths. The mortality 
rates due to multidrug-resistant bacterial infections are high. Each year about 25,000 
patients in the European Union die from an infection caused by multidrug resistant 
bacteria and more than 63,000 patients in the United States die every year from 
hospital-acquired bacterial infections8. More than 1.5 billion euros are spent each year 
as a result of extra healthcare costs and productivity losses due to infections by multi-
drug resistant bacteria9. Therefore there is a strong need for introducing new ways of 
responding to the antibiotic resistance challenge with the discovery and development 
of new therapeutic agents and a better understanding of antibiotic resistance 
mechanisms.  
ESKAPE Problem 
The Infectious Diseases Society of America has chosen a group of multi-drug resistant 
bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) and has 
given them the acronym ESKAPE because of their capability to escape bactericidal 
effects of antibiotics10.  
Enterococcus faecium 
Enterococcus faecium is a gram positive bacterium that can be commensal in the 
human intestine, but can also be pathogenic. It can also be found in the oral cavity and 
the vaginal tract. It can cause nosocomial bacteremia, surgical wound infection, 
endocarditis and urinary tract infections10. E. faecium is capable of surviving for 
extended periods in soil, sewage and inside hospital on many different kinds of 
surfaces. It is capable of growing under a wide range of environmental conditions, 
including temperatures ranging from 10 to 45 degrees Celsius, basic or acidic, 
hypertonic or isotonic environments11.  
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E. faecium can be highly drug resistant and acquires its resistance by plasmids, by 
conjugative transposons, by chromosomal genes that encode resistance and by 
sporadic mutations. There are reports that refer to E. faecium strains as being resistant 
to vancomycin12, penicillin13, gentamicin14 and teicoplanin15. For instance, high-level 
penicillin resistance in E. faecium is most commonly associated with accumulation of 
point mutations in the penicillin binding region of PBP516 (acquired resistance), in the 
contrary E. faecium is resistant to tobramycin with MICs as high as 1000 μg/ml 
because of the aminoglycoside 6’ acetyltransferase, which is encoded from its 
genome17 (intrinsic resistance). 
 
Staphylococcus aureus  
S. aureus is a gram positive coccal bacterium which is commensal in the respiratory 
tract and on the skin18. However, it can also be pathogenic and cause skin and soft 
tissue infections such as abscesses, furuncles and cellulitis. It can also cause much 
more serious infections such as bloodstream infections, pneumonia, or bone and joint 
infections19. It is one of the five most common causes of hospital acquired infections 
and is often the cause of postsurgical wound infections. Each year around 500,000 
patients in United States’ hospitals contract a staphylococcal infection20. 
S. aureus is adept at adapting quickly to antibiotic treatment. The most common 
mechanisms used by S. aureus are the enzymatic inactivation of the antibiotic, the 
decreasing of the affinity of the target molecule of the antibiotic by altering its structure, 
and efflux pumps. The genes responsible for the antibiotic resistance are acquired 
through horizontal gene transfer or by spontaneous mutations21. 
Methicillin-resistant Staphylococcus aureus (MRSA) has been a major multidrug-
resistant (MDR) pathogen since the early 1960s. Unfortunately, many MRSA 
outbreaks frequently arise with a recent example being intensive care unit (ICU)-
associated bacteremia in London22. Recent studies from Europe state that the average 
excess costs per MRSA infected patient range from 5,700 € to 10,000 €23. Methicillin, 
like all penicillins, exerts its action by blocking the penicillin binding proteins (PBPs) 
which are responsible for the construction and the maintenance of the bacterial cell 
wall. The MRSA strains acquired a gene called PBP2a which was not blocked by 
methicillin and could replace the other PBPs. The gene that encodes PBP2a is mecA 
and its presence means MRSA is not only resistant to methicillin but also to all β-lactam 
antibiotics including synthetic penicillins, cephalosporins and carbapenems24.   
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Klebsiella pneumoniae 
Klebsiella pneumoniae is a Gram negative, non-motile, rod shaped bacterium which is 
found in the nasopharynx and the intestinal tract25. However it can also be pathogenic 
and because of its ability to spread rapidly in the hospital environment, these bacteria 
tend to cause nosocomial outbreaks. It can cause urinary tract infections, septicemias, 
pneumonia, soft tissue infections, thrombophlebitis, diarrhea, upper respiratory tract 
infection and meningitis25, 26. It is also an opportunistic pathogen for patients with 
chronic pulmonary disease, enteral pathogenicity and rhinoscleroma25. Due to the 
extensive spread of antibiotic-resistant strains, especially of extended-spectrum β-
lactamase (ESBL)-producing strains, there has been renewed interest in Klebsiella 
infections27.  
Since ESBL production frequently is accompanied by multi-resistance to antibiotics, 
therapeutic options have become limited. However, ESBL-producing Klebsiella strains 
remain susceptible to carbapenems with a small number of reports referred to 
imipenem resistant K. pneumoniae strains28. ESBLs are usually plasmid mediated and 
easily transmitted among different members of the Enterobacteriaceae. Unfortunately, 
Klebsiella strains are accompanied by a relatively high stability of the plasmids 
encoding ESBLs. Long hospital stays are a serious factor for the acquisition of 
resistance25. 
Acinetobacter baumannii 
Acinetobacter baumannii is a rod shaped Gram negative bacterium which has 
emerged as one of the most troublesome pathogens for health care institutions 
globally. It has a remarkable ability to upregulate or acquire resistant determinants, 
making it one of the most threatening organisms in the current antibiotic era29. A. 
baumannii can survive in a hospital environment for prolonged periods, thus 
potentiating its ability for nosocomial spread30. The most common infection caused by 
this organism is hospital–acquired pneumonia31 but there are reports also of A. 
baumannii infecting the central nervous system, skin and soft tissue, and bones.  
A. baumannii has several mechanisms of acquiring antibiotic resistance. The most 
prevalent mechanism of β-lactam resistance in A. baumannii is enzymatic degradation 
by β-lactamases. However multiple mechanisms often work in concert to produce the 
same phenotype32. A. baumannii is intrinsically resistant to cephalosporins as all 
strains are chromosomally encoded with AmpC cephalosporiases33. As far as it 
concerns aminoglycosides, it is reported that the presence of genes encoding for 
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aminoglycoside-modifying enzymes within class 1 integrons is highly prevalent in 
multidrug resistant A. baumannii strains34. Finally, there are also reports of A. 
baumannii strains with mutations in the gyrA and parC genes which lead in the 
synthesis of a modified DNA gyrase which is stable against quinolones30.  
 
Pseudomonas aeruginosa 
P. aeruginosa is a Gram negative, motile, rod shaped bacterium which is abundant in 
various moist environments. This opportunistic pathogen is associated with hospital-
acquired infections, most notably in immunocompromised individuals35. It can cause 
urinary tract infections36, ventilator associated pneumonia34, surgical site infection34, 
ocular infections37, skin and soft tissue infections and burn sepsis38. Patients with AIDS 
or cystic fibrosis face an increased risk of acquiring an infection and developing 
complications35.  
What makes P. aeruginosa uniquely problematic is its inherent resistance to many 
drug classes, its ability to acquire resistance via mutations to all relevant treatments, 
its high and increasing rates of resistance locally and its frequent role in serious 
infections39. Mechanisms underlying antibiotic resistance have been found to include 
production of antibiotic-degrading or antibiotic-inactivating enzymes, outer membrane 
proteins to evict the antibiotics and mutations to change antibiotic targets39.  
 
Enterobacter cloacae  
Enterobacter cloacae is part of the normal flora of the gastrointestinal tract of 40 to 
80% of people and is widely distributed in the environment40. Enterobacter infections 
are increasing in frequency, particularly in intensive care units. This nosocomial 
pathogen can cause a range of infections such as bacteremia, lower respiratory tract 
infection, skin and soft tissue infections, urinary tract infections, endocarditis, intra-
abdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections41.  
The first complete genome sequence of E. Cloacae isolated from human cerebrospinal 
fluid was reported in 2010. It was reported that the organism carries genes for 37 
multidrug efflux proteins, 7 antimicrobial peptide resistance proteins, and 11 β-
lactamases, suggesting its broad range of antibiotic resistance42. A number of agents 
remain effective for treatment. Among the beta-lactams, the fourth generation 
cephalosporins and carbapenems are the most attractive options. Aminoglycosides 
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retain good activity but usually require combination with another agent. Quinolones are 
highly active against most strains, but emerging resistance is a major concern43.  
 
Antibiotics used in the experiments 
Cefepime 
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994 and 
marketed under the name Maxipime. It is usually reserved to treat moderate to severe 
nosocomial pneumonia, infection caused by multiple drug resistant bacteria such as 
P. aeruginosa. Cefepime acts by binding to penicillin-binding proteins and inhibiting 
the synthesis of the bacterial cell wall44. Zwitterionic fourth-generation cephalosporins 
combine the properties of rapid bacterial outer membrane penetration with high 
stability to AmpC β-lactamase and with good affinity for the penicillin-binding 
proteins45. Cefepime has in vitro activity against Gram-positive organisms including S. 
aureus and penicillin-sensitive, -intermediate and -resistant Streptococcus 
pneumoniae similar to that of cefotaxime and ceftriaxone44. Cefepime also has good 
activity against Gram-negative organisms, including P. aeruginosa, similar to that of 
ceftazidime. Importantly, cefepime is stable against many of the common plasmid- and 
chromosome-mediated β-lactamases and is a poor inducer of AmpC β-lactamases44. 
 
Ciprofloxacin 
Ciprofloxacin is a broad spectrum fluoroquinolone antibacterial agent which exerts its 
antimicrobial effect by preventing energy dependent negative supercoiling of bacterial 
DNA through gyrase inhibition46. Fluoroquinolones are effective agents that target both 
gram-negative and gram-positive bacteria and are recommended for severe bacterial 
infections47. Ciprofloxacin attains therapeutic concentrations in most tissues and body 
fluids. The results of clinical trials with ciprofloxacin have confirmed its clinical efficacy 
and low potential for adverse effects. These include complicated urinary tract 
infections, sexually transmitted diseases (gonorrhoea and chancroid), skin and bone 
infections, gastrointestinal infections caused by multi-resistant organisms, lower 
respiratory tract infections (including those in patients with cystic fibrosis), febrile 
neutropenia (combined with an agent which possesses good activity against Gram-
positive bacteria), intra-abdominal infections (combined with an antianaerobic agent) 
and malignant external otitis48. 
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Meropenem 
Meropenem is a carbapenem antibiotic showing a strong antibacterial activity to a wide 
range of bacteria strains from Gram-positive bacteria to Gram-negative. Carbapenems 
act as mechanism-based inhibitors of the peptidase domain of PBPs (Penicillin-binding 
proteins) and can inhibit peptide cross-linking as well as other peptidase reactions. A 
key factor of the efficacy of carbapenems is their ability to bind to multiple different 
PBPs49. A remarkable feature of meropenem is that its toxicity to the central nerve and 
the kidney are significantly low, while conventional carbapenem antibiotics are 
problematic in these toxicities50.  
 
Tetracycline 
Tetracycline is a broad spectrum polyketide antibiotic which exhibits activity against a 
wide range of microorganisms including Gram-positive and Gram-negative bacteria, 
chlamydiae, mycoplasmas, rickettsiae, and protozoan parasites50. The first 
tetracycline-resistant bacterium, Shigella dysenteriae, was isolated in 1953. 
Tetracycline resistance now occurs in an increasing number of pathogenic, 
opportunistic, and commensal bacteria. The presence of tetracycline-resistant 
pathogens limits the use of this agent in treatment of disease. Tetracycline inhibits 
protein synthesis by preventing the attachment of aminoacyl-tRNA to the ribosomal 
acceptor (A) site50. Tetracycline resistance is often due to the acquisition of new genes, 
which code for energy-dependent efflux of tetracyclines or for a protein that protects 
bacterial ribosomes from the action of tetracyclines51. 
 
Gentamicin 
Gentamicin is an aminoglycoside antibiotic produced by Micromonospora purpurea. It 
was discovered in 1963 by Weinstein, Wagman et al. at Schering Corporation in 
Bloomfield, N.J. 52. Gentamicin is a bactericidal antibiotic that works by irreversibly 
binding the 30S subunit of the bacterial ribosome, interrupting protein synthesis53. An 
important characteristic of this drug is its capability to remain active even after 
autoclaving54. The mechanisms of resistance to gentamicin are: decreased cell 
permeability, alterations at the ribosomal binding site and aminoglycoside modifying 
enzymes found on plasmids and transposons55.   
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Thesis Investigations 
Although we know the ESKAPE pathogens possess a remarkable ability to acquire 
resistance for a broad range of antibiotics, few adaptive evolution studies have ever 
been performed on these medically important species. The information we have about 
the mechanisms of resistance come from highly resistant clinical isolates that have 
been sequenced. In my thesis work I performed a systematic adaptive evolution of the 
ESKAPE organisms under uniform growing conditions using the aforementioned suite 
of antibiotics. Populations were adapted to each one of the five drugs. Drug 
combinations were not investigated here. Following adaptation, individual isolates of 
the most resistant populations were investigated for collateral sensitivity and 
resistance to the four other antimicrobials. The purpose of this research is to shed light 
on the evolutionary path that leads to resistance acquisition in the ESKAPE organisms. 
 
Overall image of the adaptive evolution experiments 
Table 1: Adaptive evolution experiments. S. aureus to cefepime and K. pneumoniae to Meropenem needed to be 
redone 
 
Table 1 includes the 30 adaptive evolutions that were performed for the project by 
Marius Faza, former employee of Systems Biology department in DTU. Two of them 
failed, marked with a cross in table 1, and therefore needed to be redone.   
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Materials and Methods 
Bacteria and Reagents 
S. aureus strain Newman and K. pneumoniae (DSM 30104) were adapted to cefepime 
and meropenem, respectively. MICs tests and kinetic experiments were performed to 
six bacterial organisms: E. faecium (DSM 2146), S. aureus strain Newman, K. 
pneumoniae (DSM 30104), A. baumannii (ATCC 17978), P. aerugnosa (PAO1) and E. 
cloacae (ATCC 13047). The drugs used in these experiments were: cefepime, 
meropenem, tetracycline, gentamicin and ciprofloxacin. All adaptive evolution 
experiments, MICs and kinetics experiments were performed using Mueller – Hinton 
Broth (MHB) media with an addition of 0.5% glucose. The drug stocks were refreshed 
every ten days.  
Adaptive Evolution Experiments 
Before the beginning of the evolution experiments it was necessary to determine the 
IC90 of the wild type (WT) strains. Therefore, MIC experiments were established for 
S. aureus to cefepime and K. pneumoniae to meropenem. Twenty four well plates were 
used for the evolution experiments. Both adaptive evolutions were performed in 
triplicates. Positive and negative controls accompanied every adaptation experimental 
step. The negative control included media only and was used as an indicator of 
contamination and as a way to measure the optical density of pure media. The positive 
control, apart from the media, contained 75 μl of the inoculating strain. The inoculating 
strains were subjected to increasing drug concentrations in two-fold steps. After an 
eighteen hour incubation period at 37 oC, the optical density (OD) at 600 nm 
wavelength was measured on a BioTek Epoch plate reader. The value of the positive 
control was used to normalize the evolution data. In order to determine the well, from 
which the next day’s experiment would be inoculated, a maximum limit of 60% bacterial 
inhibition was chosen. This value was selected based on previous work56. The replicate 
that presented the best growth below and closer to the 60% inhibition cut off (passage 
value) was used as the inoculating material for the next experiment. For each replicate 
eleven wells were used, two for the negative and positive controls and nine for the 
increasing concentrations of which three were below the previous day’s passage 
value, in two fold steps. 50 μl volume of the passaged well was inoculated into 5000 μl 
of fresh media containing the passage concentration of the drug and the solution was 
incubated overnight at 37 oC. A portion of the overnight culture was saved in glycerol 
stocks. This same process was repeated eighteen times for both evolution 
experiments.   
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Collateral Sensitivity and Resistance Experiments  
Bacterial isolates from the last evolution step, which had been saved as glycerol 
stocks, were tested to determine their IC90 fold improvement over the IC90 of the non-
adapted WT. Every adapted strain was also tested to the other antibiotics to determine 
if adaptation to one drug resulted in cross resistance to another. In order to determine 
the IC90 of the adapted strains we used 96 well micro titer plates and the experiments 
were performed in quadruplicates. The concentration of the drugs for each experiment 
followed a two-fold steps mode. Similarly to the adaptive evolution experiments 
positive and negative controls were used in each test. Adapted strains from the glycerol 
stocks were streaked into LB petri plates and incubated at 37oC overnight. Four 
colonies from each plate were picked, inoculated into MHB+0.5% glucose media and 
incubated at 37oC for 4 – 6 hours. After the growth period the pre-cultures were diluted 
and used as inoculant for the 96 well micro titer plates. The inoculated plates were 
incubated at 37oC overnight for at least 16 hours and after the growth period OD600 
was read on a BioTek Epoch plate reader. 
 
Kinetics Experiments 
Kinetic experiments were performed for all the adapted strains in order to calculate the 
generation time G and the growth rate k. All kinetic experiments were performed in 96 
well micro titer plates in quadruplicates. Adapted strains from the glycerol stocks were 
streaked into LB petri plates and incubated at 37 oC overnight. A single colony was 
picked, inoculated into MHB+0.5% glucose media and incubated at 37 oC for 4 – 6 
hours. After the growth period this solution of cells was used as inoculant for the 96 
well micro titer plates. The inoculated plates were placed in Elx808 BioTek plate reader 
at 37 oC, shaking for a certain period of time (All E. faecium isolates were incubated 
for 14 hours without shaking. All other isolates were incubated for 12 hours, shaking) 
and OD630 was measured every 5 minutes.  
 
Data Analysis 
For the analysis of the experimental data Excel and Prism software was used. First, 
from all the OD600 values of the inoculated wells the average value of the negative 
controls was subtracted. The resulting values were then divided by the positive control 
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OD600 value. The result of the division is the fraction of cells able to grow at a particular 
drug concentration.  Inhibition is calculated as: 1-fraction of cell survivors. Inhibition 
data were plotted in Prism and IC90 was read from the graph. 
The OD630 values from the kinetic experiments were plotted in Prism and the time 
values at 0.1 OD630 and 0.25 OD630 were read from the accrued graph. Generation 
time is calculated as:  𝐺 =
𝛥𝑡
3.3•log (
𝑁0.25
𝑁0.1
)
 . Where Δt = time of 0.25 OD630 – time of 0.1 
OD630 and N = concentration of cells. Growth rate is calculated as: 𝑘 =
2.303•log (
𝑁0.25
𝑁0.1
)
𝛥𝑡
 
 
Adaptive Evolution of S. aureus to Cefepime 
S. aureus strain Newman was isolated in 1952 from a human infection and since then 
has been used in a variety of experiments57. Its genome sequence was published in 
2008 (Journal of Bacteriology by Tadashi Baba et al.) and showed that Newman lack 
antibiotic resistant determinants compared to MRSA58. Recently, five genes have been 
found to confer antibiotic resistance, though none of them are β-lactamases59. 
 
Determining WT MIC  
Prior to the adaptation process the Inhibitory Concentration 90% (IC90) of the WT 
strain to cefepime needed to be determined. This was done for two reasons. First, all 
the data gathered for the adapted strains, were compared to the IC90 of the non-
adapted strain, secondly, the WT IC90 provided a starting point for our adaptation 
experiment.  
The IC90 experiment was performed in a micro titer 96 well plate, the plan of which is 
presented in figure 1.  
 
Figure 1: 96 well micro titer plate’s plan 
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The negative control was placed in column 1 and the positive control in column 2. 
Column 3 to 12 contained increasing concentrations of cefepime. Concentrations 
increased between columns in two fold steps so that a very broad range of values 
could be covered. The experiment was performed using four technical replicates. The 
results of this experiment are presented in figure 3, from which we determined that the 
IC90 of the WT strain of S. aureus to cefepime was 1.45 μg/ml.  
 
Figure 2: Inhibition of Staphylococcus aureus WT in a gradient of cefepime concentrations. Determination of IC90 
at 1.45 μg/ml 
. 
 
Explanation of the adaptive evolution experiment – Day 1 
The adaptive evolution experiments were performed in 24 well plates, the template of 
which is presented in figure 3.  
 
16 
 
 
Figure 3: 24 well plate’s template 
A single S. aureus colony was grown up overnight and then used as inoculant in the 
evolution experiments. The experiment was performed in triplicate and gave rise to 3 
lineages: A, B and C. Each evolution step used two 24-well plates. The highest 
concentration was placed in the first plate in column 6 to allow for a larger 
concentration range to be tested. For instance, the highest drug concentration of 
lineage A was placed in well A6, of lineage B in well B6 and of lineage C in well C6. 
Concentrations then decreased in two-fold steps across plates 1 and 2. In row D on 
plate 1 the first three wells were used as negative controls and the well D4 was used 
as positive control for lineage A, well D5 as positive control for lineage B and well D6 
as positive control for lineage C. The determined IC90 concentration was used to 
center the concentration range considered in Day 1 of the evolution experiment. The 
concentrations chosen for Day 1 are presented in Table 2. Each well contained 1500 
μl of the appropriate drug concentration in MHB+0.5% glucose media (except for the 
negative and positive controls that contained pure media without drug). Apart from the 
negative controls, the rest wells were inoculated with 75 μl of S. aureus WT.  
 
Table 2: Template of the two 24 well plates for Day’s 1 experiment. The values in the blue boxes are concentrations 
of cefepime in μg/ml 
 
Following 16 hours of incubation at 37 oC, we measured the OD600 of the wells and 
the results of Day 1 are presented in Table 3. 
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Table 3: Calculation of OD600 from Epoch Plate Reader for Day 1 (Values in white cells). On the top (blue cells) the 
values refer to the concentration of cefepime in the wells of the same column. D row of Plate 1 contains the negative 
and positive controls as shown in Table 2. 
 
An average of the three negative controls was taken and subtracted from the remaining 
values. The resulting values were then normalized by their respective positive control, 
so all values from lineage A were divided by the positive control of lineage A, the values 
from lineage B by the positive control of lineage B and the values from lineage C by 
the positive control of lineage C. The results were then subtracted from 1 in order to 
determine the fraction of the population inhibited by the drug concentration. The results 
for Day 1 are presented in Table 4. 
Table 4: Percentage of inhibition in each well.  
 
We used the following criteria to determine which wells would be used as inoculum in 
the next evolution experiment: the highest concentration for which no more than 60% 
inhibition was present. In Day 1 the wells with 0.5 μg/ml cefepime concentration for all 
three lineages were selected. 
 
Explanation of the adaptive evolution experiment – Day 2 to Day 18 
The passaged concentration from Day 1 was placed in column 1 of plate 1. In this case 
0.5 μg/ml for all three lineages. The other concentrations follow the two-fold increasing 
and decreasing method as in Day 1. Each lineage was inoculated using the selected 
well of the previous day into a new plate. For example, all the wells referred to lineage 
A (Plate 1: A1 to A6 and D4, Plate 2: A4 to A6) were inoculated from the passaged 
well of Day 1 (A1 from Plate 1 in our case). The same pattern applied for lineages B 
and C. The inoculation of Day 2 plates is presented in figure 4. The same process was 
repeated until Day 18, which was the last adaptation day of this experiment. The 
passage wells were determined with the 60% criteria after analysis of the data in 
Microsoft Excel. 
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Figure 4: Inoculation of Day 2. Lineage A: GREEN, Lineage B: RED, Lineage C: YELLOW 
 
Results after the completion of the adaptation  
The adaptation of S. aureus to cefepime lasted 18 days and the results for each lineage 
are presented in figure 5. 
 
Figure 5: Adaptation of Staphylococcus aureus strain Newman to cefepime. Passage drug concentrations graph. 
Dash line refers to the ECOFF of Staphylococcus aureus to cefepime which is 8 μg/ml (EUCAST) 
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We observe that the three lineages differed in their adaptation to cefepime. This is to 
be expected because S. aureus is a living organism with a complicated metabolic 
network and broad range of genetic mechanisms. A possible explanation for this 
variation could be that the mutations which occurred in lineage C did not confer high 
levels of resistance to cefepime where as the mutations that occurred in lineages A 
and B did. Following 18 days of adaptation lineage A could grow in 16 μg/ml of 
cefepime, lineage B could grow in 32 μg/ml and lineage C could grow in 4 μg/ml. 
Following 18 days of exposure, all three lineages reached or surpassed the clinical 
MIC breakpoint of Staphylococcus aureus to cefepime given by EUCAST (4 μg/ml)60. 
Clinical antimicrobial susceptibility breakpoints are used to predict the clinical outcome 
of antimicrobial treatment.   
 
Another important parameter concerning antibiotic resistance is the epidemiological 
cut-off (ECOFF) value, as it is acronymically labelled by EUCAST. ECOFF values are 
bacteria and drug specific and represent the highest value within a WT MIC 
distribution. The ECOFF of S. aureus to cefepime is 8 μg/ml and the distribution is 
presented in Figure 660. Lineages A and B surpass the ECOFF value and can be 
considered clinically resistant. 
 
Figure 6: MIC distribution of S. aureus to cefepime from 38 data sources published by EUCAST 
Adaptation of S. aureus to cefepime was rapid. Lineages A and B exceeded ECOFF 
value after 13 days, an observation that confirms that this bacteria has the ability to 
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evolve multi-drug resistant mechanisms. It is likely that this resistance was achieved 
via mutations affecting the affinity of cefepime’s binding to penicillin binding proteins, 
however, without sequencing data we cannot be sure of this. 
 
MIC of the adapted S. aureus strain Newman lineages to cefepime 
Following the completion of the adaptation procedure we investigated how the IC90 of 
the three lineages changed after 18 days of exposure to cefepime. MIC experiments 
were performed for lineages A, B and C to cefepime. The results of the MIC tests are 
presented in Figure 7. The IC90 of lineage A was determined to be 85 μg/ml, lineage 
B was determined to be 65 μg/ml and lineage C was determined to be 20 μg/ml. 
Lineages A and B adapted to a higher cefepime concentration than lineage C. It is 
unsurprising that their respective IC90 values would be greater than lineage C. 
Relative to the WT, the fold improvement of lineage A was 59x WT IC90, of lineage B 
was 45x WT IC90 and of lineage C was 14x WT IC90. 
 
 
 
Figure 7: MIC test of Lineages A, B and C to cefepime after 18 days of adaptation 
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Adaptive Evolution of K. pneumoniae to meropenem 
Information about K. pneumoniae (DSM 30104) 
K. pneumoniae (DSM 30104) is a clinical isolate whose genome was published at 
Journal of Bacteriology in 201262. Fifteen antibiotic resistance genes were identified 
within its genome, including genes coding for class A beta-lactamase, a multidrug 
resistant efflux pump and a potassium antiporter. There were also 10 genes related to 
lactamase function, including gloB and ampC, which have the functions of encoding a 
metallo-beta-lactamase superfamily hydrolase and beta-lactamase class C, 
respectively62. 
 
K. pneumoniae WT MIC test 
An MIC test was performed for K. pneumoniae to meropenem before beginning of the 
adaptive evolution experiment. The IC90 was determined at 0.033 μg/ml (Figure 8). 
 
Figure 8: MIC test of Klebsiella pneumoniae WT to meropenem 
 
K. pneumoniae adaptive evolution experiment 
The procedure that was followed for the 18 days adaptive evolution of K. pneumoniae 
to meropenem was the same as in the case of S. aureus to cefepime. Results of the 
adaptation are presented in Figure 9. 
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Figure 9: Adaptive evolution of Klebsiella pneumoniae to meropenem. Y axis: Passage concentration (μg/ml), X axis: 
exposure (days). The dashed line represents the ECOFF value, which is at 0.125 μg/ml 
Lineage A adapted quickly to meropenem, and then at Day 7 a big drop in the passage 
concentration appeared. After this drop or valley, lineage A steadily started to adapt in 
higher drug concentrations. Lineage B experienced two adaptation valleys, one at Day 
7 and one at Day 9. Thereafter, the drug concentration increased up to Day 16, when 
it started dropping again. Lineage C had one adaption valley starting from Day 7 and 
continuing until Day 10. Thereafter it adapted steadily to higher drug concentration 
reaching a maximum value at Day 15.  
Every day we selected the strongest population to passage and this choice lead to 
adaptation bottlenecks. What we observe here is that resistance comes at a cost to 
the organism and this cost is manifested as slower growth or weaker growth. The 
adaptation valleys represent this phenomenon.  
Following 18 days of adaptation lineages A and C were able to grow in 3.2 μg/ml of 
cefepime, while Lineage B was able to grow in 0.8 μg/ml. 
The epidemiological cut off (ECOFF) for meropenem tested in Klebsiella pneumoniae 
is 0.125 μg/ml given by EUCAST63.  
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Figure 10: MIC distribution of Klebsiella pneumoniae to meropenem published by EUCAST 
In our adaptive evolution experiment all lineages surpassed the ECOFF value. This 
observation confirms that all our lineages became clinically resistant to meropenem. 
The main mechanisms of resistance in our case were likely β-lactamases since 
carbapenems are β-lactam antibiotics and from previous work our strain was known to 
possess GloB, AmpC and 8 more genes that code for β-lactam resistance62. 
 
MIC test of the adapted K. pneumoniae lineages to meropenem 
Following the adaptation process we determined the fold improvement of the IC90 
value of all three lineages over the WT IC90 using MIC tests. The results are presented 
in Figure 11. The IC90 for lineage A was at 4 μg/ml and 2.6 μg/ml for lineages B and 
C, indicating that adaptation was nearing its end. This corresponds to a fold 
improvement of 121 times for lineage A and 79 times for lineages B and C. All three 
lineages became more than 50 times more resistant to meropenem than the non-
adapted WT strain. 
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Figure 11: MIC test of K. pneumonia to meropenem lineages A, B, C after 18 days of exposure. 
 
Introduction to Cross Resistance and Sensitivity Experiments 
Apart from the two adaptive evolutions that we performed, 28 additional adaptive 
evolutions had already been done by Marius Faza, a postdoc in the Sommer Lab. 
Isolates of all adapted populations were tested to the drug they were adapted to and 
to the four other drugs used in this work. The information derived from these 
experiments help us to understand how resistance amongst different classes of drugs 
is related. The bacteria used in these experiments are E. faecium (DSM 2146), 
Staphylococcus aureus strain Newman, K. pneumoniae (DSM 30104), A. baumannii 
(ATCC 17978), P. aerugnosa (PAO1) and E. cloacae (ATCC 13047). The drugs used 
in these experiments were: cefepime (cephalosporin), meropenem (carbapenem), 
tetracycline (polyketide), gentamicin (aminoglycoside) and ciprofloxacin 
(fluoroquinolone).  From now on in the thesis the drugs will be also referred with their 
acronyms, Cefepime – FEP, Meropenem – MEM, Tetracycline – TET, Gentamicin – 
GEN and Ciprofloxacin – CIP.  The target of each drug is presented in Table 5. 
Although they belong to different classes of antibiotics, the targets of FEP and MEM, 
and GEN and TET were common. Necessary for the following analysis are the WT 
IC90s of the WT strains, which are presented in Table 6. 
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Table 5: target of each antibiotic in the bacterial cells 
 
 
Table 6: WT IC90s of all species to the suite of drugs. Values are in μg/ml 
 
 
Cross Resistance of Staphylococcus aureus (Newman)  
Results of the collateral sensitivity and resistance tests for all adapted S. aureus strains 
are shown in Figure 12. The color of the cells represent the intensity of the fold 
susceptibility or the fold resistance over the WT strain. Cells that have shades of blue 
show that the adapted stain is more susceptible and cells that have shades of brown 
show that the adapted strain is more resistant. Heat map values represent an average 
IC90 of four biological replicates divided by the WT IC90 of the selected drug. These 
values reflect resistance or sensitivity gained as a result of adaptation to a single drug.  
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Figure 12: Cross resistance/susceptibility of S. aureus strain Newman to FEP CIP MEM GEN and TET  
Adaptation to FEP confers cross-resistance to MEM and TET (lineages A and C). 
Adaptation to CIP confers slight cross resistance to GEN. The IC90 of CIP adapted to 
CIP was more than 103 times the WT. Adaptation to GEN does not result in collateral 
resistance or susceptibility. Adaption to MEM confers slight cross-resistance to GEN. 
TET adaptation resulted in MEM cross resistance in two out of four lineages. Overall 
adaptation of S. aureus to antimicrobial environments results in limited cross-
resistance and in no collateral sensitivity. 
 
 
Cross Resistance of Acinetobacter baumannii (ATCC 17978) 
A. baumannii strain ATCC 17978 was isolated from a case of meningitis in 1951. Its 
sequence was published in 200764. It was reported that A. baumannii ATTCC 17978 
possessed 74 potential drug-resistant genes, including 32 efflux pumps and 11 
permeases of the drug/metabolite transporter (DMT) superfamily. This strain is also 
reported to be resistant to β-lactams and have weak resistance to tetracycline and 
aminoglycosides. The cross-resistance of A. baumannii to our suite of drugs is 
presented in Figure 13. 
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Figure 13: Heatmap: Cross resistance/susceptibility of A. baumannii to FEP CIP MEM GEN and TET 
Adaptation of A. baumannii to FEP resulted in an increase of WT IC90 by 8 to 20 times, 
but resulted in collateral cross resistance to GEN (16-39x WT IC90). Additional notable 
cross-resistance was observed at CIP (>5x WT IC90). IC90 of CIP adapted to CIP is 
104 times the WT. In addition, adaptation to CIP confers cross-resistance to the 
remaining drugs. Adaption to GEN confers resistance to FEP and CIP. After the 
adaptive evolution of A. baumannii to GEN the IC90 increased from 4813 times in 
lineage B up to 8750 times in lineage C. The strains adapted to MEM became more 
than 10 times more sensitive to TET. Adaption to MEM also confers resistance to FEP, 
CIP and GEN. Although the evolution of resistance to FEP is explainable because they 
both are β-lactam antibiotics and therefore share common target, the increased 
susceptibility in TET needs further research. Adaption to TET confers slight resistance 
to FEP, CIP and MEM. The presence of several genes in A. baumannii may explain 
the collateral resistance and sensitivity observed here.  
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Cross Resistance of Enterococcus faecium (DSM 2146) 
The genome of E. faecium DSM 2146 has not been sequenced, so we do not know if 
it has any resistance genes. The first E. faecium whole-genome sequence was 
published in 2012 (by Margaret M. C. Lam in Journal of Bacteriology)65.  It was a strain 
isolated from a patient’s bloodstream in Australia reported to have the vancomycin 
resistant gene VanB. Later in 2012 the complete genome sequence of E. faecium 
TX16 (also referred as DO) was published66. This is an isolate from a hospitalized 
patient with endocarditis. Four tetracycline resistance genes were reported related to 
tetracycline efflux pumps. The results from our cross resistance experiments in E. 
faecium are presented in figure 14.  
 
 
Figure 14: Heatmap: Cross resistance/susceptibility of E. faecium to FEP CIP MEM GEN and TET 
Adaptation to FEP resulted in 20 times cross-resistance to MEM. Adaptation to CIP 
confers very strong cross resistance to FEP (100x WT IC90) and more moderate 
cross-resistance to MEM (6x WT IC90) and TET (5x WT IC90). Adaptation to GEN 
resulted in 20x IC90 in FEP and also confers resistance to MEM (WT IC90) and TET 
(4x WT IC90). Adaptation to MEM confers cross-resistance to FEP. Finally, E. faecium 
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adapted to TET, not only, conferred a slight cross resistance to MEM (2-6x WT IC90) 
and CIP (2x WT IC90), but also a slight cross sensitivity to FEP (2x WT IC90). 
Firstly, notable is that adaptation of E. faecium to TET did not result in large 
improvement in IC90. Secondly, E. faecium developed resistance to FEP after 
adaption to CIP, GEN and MEM. We know that carbapenems and cephalosporins have 
the same mechanism of action which may explain the cross resistance between FEP 
and MEM. However, it is difficult to explain, without sequencing data, why resistance 
to a fluoroquinolone or an aminoglycoside leads to cross-resistance to FEP. In a 
publication by LB Rice et al., it is stated that E. faecium amplifies its resistance against 
β-lactam antibiotics with combinations of mutations in PBP5 gene67. However, there is 
no evidence that adaptation to CIP or GEN results in mutations to the PBP5 gene. 
 
Cross Resistance of Pseudomonas aeruginosa (PAO1) 
Strain PAO1 is a wound isolate and the most widely used strain of P. aeruginosa. Its 
genome was published in 200068. There are 34 known resistance genes occurred with 
the majority being related with multi-drug resistant efflux pumps achieved by outer 
membrane proteins. The researchers stated that P. aeruginosa contains the highest 
proportion of regulatory genes observed for a bacterial genome. These regulatory 
genes may play a role in resistance adaptation. 
Analysis of the cross resistance of P. aeruginosa PAO1 was performed and the data 
derived from our study are presented in Table 9. Adaptation to FEP limited cross-
resistance to other drugs. Out of four lineages only lineage C surpassed more than 10 
times the IC90 value of the WT strain. Adaptation to CIP resulted in cross-resistance 
to TET (4-8x WT IC90) and FEP (8-16x WT IC90). Adaptation to GEN confers slight 
cross-resistance to the remaining drugs (3-6x WT IC90). Strains adapted to MEM 
gained cross-resistance to TET (15x WT IC90) and a slight cross resistance to FEP 
(4-7x WT IC90) and CIP (4x WT IC90). Adaptation to TET confers cross-resistance to 
all remaining drugs. 
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Figure 15: Heatmap: Cross resistance/susceptibility of P. aeruginosa to FEP CIP MEM GEN and TET 
P. aeruginosa has  difficulty evolving strong antibiotic resistance mechanisms against 
FEP and it is for this reason that it is commonly used against this specific bacteria. The 
ECOFF value of P. aeruginosa to FEP is 8 μg/ml and apart from lineage C none of the 
remaining three lineages surpassed it. In research published in the journal of 
Antimicrobial Chemotherapy in 2002, scientists stated that the pharmacodynamics 
profile of cefepime predicts acceptable levels of success against P. aeruginosa69. In a 
similar study with extended-infusion cefepime used as treatment for P. aeruginosa 
infections, the results showed that cefepime reduces mortality, reduces the mean time 
of stay in the intensive care unit by 3.5 days and reduces the hospital costs by  $ 
23,183per person70.  
 
 
Cross Resistance of Enterobacter cloacae (ATCC 13047) 
E. cloacae (ATCC 13047) was isolated from human cerebrospinal fluid by Edwin 
Oakes Jordan in 1890. The genome of this strain was published in 201042. This strain 
has a broad range of antibiotic resistance mechanisms including efflux pumps and β-
lactamases. E. cloacae was challenged to the suite of 6 drugs that we used and the 
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adapted strains were tested for possible development of collateral sensitivity or 
resistance.  
The data we gathered from the MIC experiments are presented in figure 16. 
 
 
Figure 16: Heatmap: Cross resistance/susceptibility of E. cloacae to FEP CIP MEM GEN and TET 
 
Adaptation to FEP results in a cross sensitivity to GEN (2-5x WT IC90) and cross 
resistance to MEM (3x WT IC90). CIP adapted strains became 5 to 10 times more 
sensitive to GEN. Adaptation to GEN confers cross-resistance to FEP (4x WT IC90). 
We also observed an unequal bidirectional collateral resistance between FEP and 
MEM, which was stronger for MEM adapted strains (43 – 85x WT IC90). Finally, 
adaptation to TET resulted in cross-resistance to FEP (4-15x WT IC90) and CIP (10-
38x WT IC90). 
Compared to MEM, FEP is a more stable and strong β-lactam antibiotic against E. 
cloacae. We observe that the lineages adapted to MEM had greater cross-resistance 
to FEP than lineages adapted to FEP. This observation suggests that carbapenem 
resistant E. cloacae should not be treated with cephalosporins such as cefepime.  
Another observation that we should highlight is the one direction increased resistance 
of TET adapted lineages in CIP, a fluoroquinolone that targets DNA gyrase and 
topoisomerase IV. The main mechanism of resistance to quinolones is accumulated 
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mutations in gyrA, gyrB, parA and parC genes71. However, the possibility that adaption 
to TET leads to accumulated mutations in these genes unlikely. Thus, we can attribute 
this resistance increase to mutations related with cell wall permeability, such as efflux 
pumps. Sequencing results will clarify this. 
 
Cross Resistance of Klebsiella pneumoniae (DSM 30104) 
K. pneumoniae (DSM 30104) is a multi-drug resistant strain as previously stated. 
Following the adaptive evolution to each one of the drugs, we tested the collateral 
sensitivity and resistance of each adapted strain. The collected data are presented in 
Figure 17. 
 
Figure 17: Cross resistance/susceptibility of K. pneumoniae to FEP CIP MEM GEN and TET 
 
Strains adapted to FEP develop stronger resistance to MEM (10-45x WT IC90) and 
TET (14-22x WT IC90) than FEP (2-15x WT IC90). Resistance to CIP and GEN 
remains at the same levels as the WT. Adaption to CIP results in 16 times cross 
sensitivity to FEP. Cross-resistance to TET (3-5x WT IC90) and cross sensitivity to 
GEN (4x WT IC90) were also observed.  Adaptation to GEN confers cross resistance 
to MEM (2-6x WT IC90) and TET (2-5x WT IC90) and cross sensitivity to FEP (4-25x 
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WT IC90). Adaptation to MEM results in strong cross-resistance to TET (23-26x WT 
IC90) and cross-resistance to FEP (3-6x WT IC90) and CIP (2-7x WT IC90). 
Adaptation to TET confers a cross-resistance to MEM (2-7x WT IC90) and strong cross 
sensitivity to FEP (14x and 20x WT IC90) for two out of four lineages.  
The reason for which three out of four adaptations lead to collateral sensitivity to FEP 
is that the WT strain had an IC90 value, which is 10 times the ECOFF value. This 
means that DSM 30104 is FEP resistant. In order to understand what exactly 
happened we need sequencing results. The bidirectional cross-resistance between 
FEP and MEM has already been explained previously. Other observed instances of  
cross resistance may be the result of general resistant mechanisms like efflux pumps. 
 
Overall Collateral Sensitivity and Resistance Data Correlation 
Apart from the heatmaps that provide an inner species overview and constitute an 
important source of information for the collateral effects of antimicrobial exposure, we 
are also interested in how adaptation to a single drug resulted in cross resistance or 
cross sensitivity to other drugs across all the species. We, therefore, constructed 
graphs for each antibiotic including the fold IC90 change of all the bacteria in the other 
four drugs. 
 
Bacteria adapted to FEP
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Figure 18: Fold IC90 change of FEP adapted bacteria to the rest of the drugs 
Adaptation to FEP has collateral effects to CIP only in the cases of P. aeruginosa and 
A. baumannii. A. baumannii has the highest fold IC90 change in this case, but still the 
IC90 value is not 10x higher than the WT’s. A. baumannii is also the only species to 
which adaption to FEP resulted in 30 times increased resistance to GEN. The other 
bacteria remain almost equally resistant to GEN as the WT strain. Another interesting 
observation that derives from the graph is that adaption to FEP caused 27x fold IC90 
change for both K. pneumoniae and E. faecium. This is may be caused from mutations 
to some common genes in both bacteria. Sequencing data are needed to explain in 
depth these findings. In general, adaptation to FEP results in cross-resistance to MEM. 
Finally, K. pneumoniae is the only species that developed more than 10 times 
increased resistance to TET after adaptation to FEP. Four out of six species gained 
resistance to TET after adaptation to FEP. Overall adaptation to FEP did not cause 
collateral sensitivity to any combinations of bacteria and drugs except for E. cloacae 
and S. aureus to GEN. 
 
 
 
 
Bacteria adapted to CIP 
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Figure 19: Fold IC90 change of CIP adapted bacteria to the rest of the drugs 
Adaptation to CIP resulted in collateral sensitivity to GEN in both E. cloacae and K. 
pneumoniae and cross-resistance to the remaining species. K. pneumoniae also 
became sensitive to FEP. However, strong cross-resistance to FEP was observed in 
E. faecium after adaptation to CIP. Equally interesting is that adaption to FEP for both 
of the aforementioned bacteria resulted in no collateral effects to CIP (figure 18). 
Cross-resistance to MEM was observed for three out of six species. Finally, adaptation 
to CIP resulted in cross-resistance to TET in all species. Only three cases of cross 
sensitivity occur and therefore, overall adaptation to CIP results in collateral resistance 
in the majority of the cases. 
 
 
 
 
 
 
 
 
 
Bacteria adapted to GEN 
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Figure 20: Fold IC90 change of GEN adapted bacteria to the rest of the drugs 
Adaptation to GEN resulted in cross-resistance to FEP, CIP and MEM in four out of six 
species and cross-resistance to TET in three out of six species. Cross sensitivity 
occurred only in three cases. Overall adaptation to GEN resulted in cross-resistance 
to the majority of the species and drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteria adapted to MEM 
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Figure 21: Fold IC90 change of GEN adapted bacteria to the rest of the drugs 
The most important observation from Figure 21 is that MEM adaptation results in cross-
resistance to FEP across the species, which is very strong in E. faecium. Slight cross-
resistance across the species appeared also in the case of CIP. No trends occurred 
for GEN and TET. Overall adaptation to MEM resulted in cross-resistance to the 
majority of the cases. Cross sensitivity was only observed in a single case. 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteria adapted to TET 
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Figure 22: Fold IC90 change of TET adapted bacteria to the rest of the drugs 
Adaptation to TET resulted in cross-resistance to MEM across the species (apart from 
E. cloacae). It also caused cross-resistance to CIP in four out of six species. Finally, 
adaptation to TET did not cause any trends of cross resistance or cross sensitivity to 
FEP with three values being in the resistance side, two in the susceptibility side and 
one neutral. 
Growth Experiments 
The effects of adaptation on growth rate (k) and generation time (G) were investigated. 
The purpose of these experiments was to locate any adverse effects in the growth 
kinetics of the strains exposed to antibiotics. If an organism grows very slowly as a 
result of resistance adaptation then it will likely be outcompeted in an environment 
containing unadapted species. The experimental method used in order to extract the 
G and k values is explained in the Materials and Methods section. However, an 
example will be presented analytically for the better understanding of the procedure. 
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Staphylococcus aureus strain Newman adapted to FEP growth experiments 
S. aureus strain Newman adapted to FEP lineages A, B, C and WT were streaked in 
LB plates and grown overnight at 37 oC. A single colony was then picked from each 
petri plate and inoculated in MHB + 0.5% glucose liquid media and incubated at 37 oC 
for 4 to 6 hours. The pre-culture was then diluted to approximately 103 cells/μl and 10 
μl of this diluted pre-culture was used as an inoculant for a 96 micro titer well plate 
filled with media. The experiment was performed in quadruplicate technical replicates. 
The inoculated plate was placed in Elx808 BioTek plate reader shaking at 37 oC for 12 
hours and OD630 was measured every 5 minutes. The data gathered from the plate 
reader were exported to Prism software and then was used to create the kinetic 
graphs. The growth curves for S. aureus adapted to FEP and S. aureus WT are 
presented in Figure 23. 
 
Figure 23: Growth curves for S. aureus strain Newman WT and FEP adapted lineages A, B, C 
 
From the graphs we can observe that the FEP adapted strains grow faster than the 
WT strain. This is an interesting observation as it shows that resistance adaptation did 
not have a negative effect to the growth rate of S. aureus.  
For each curve the 0.1 OD630 and the 0.25 OD630 were determined and then used 
to calculate the generation time and growth rate (Materials and Methods section).  
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Table 12: Minutes of growth needed for each strain to reach 0.1 and 0.25 OD630 
 
Using the time values we calculate the generation time and the growth rate. A 
generation time is the time it takes for one cell to become two. Growth rate k is derived 
from the first grade differential equation that characterizes the exponential growth 
period. 
Table13: Generation time G and growth rate k for S. aureus strain Newman WT and lineages A, B, C adapted to 
FEP 
 
Large G values and low k values indicate slow growth. From table 13 we confirm our 
previous observation that the WT strain grows slower than the strains adapted to FEP. 
Overall growth experiments 
The same procedure, described in the previous section, was performed for all the 
adapted strains. The calculated k and G values for each strain were used to determine 
how resistance adaptation affects the kinetics growth of adapted populations. Growth 
values were used to draw general conclusions about adaptation to a particular drug 
and about the species overall. 
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Figure 24: k fold over WT for strains of each bacteria adapted to FEP 
From Figure 24 we observe that adaptation to FEP resulted in slower growth for A. 
baumannii, E. cloacae and K. pneumoniae. On the other hand, the growth rate 
increased in the cases of E. faecium and S. aureus. Adaptation to FEP had no effects 
on the growth rate of P. aeruginosa. 
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Figure 25: k fold over WT for strains of each bacteria adapted to CIP 
Overall CIP adaptation slows growth. The only exception observed is S. aureus whose 
growth rate is increased 1.2x WT. K. pneumoniae adapted to CIP was not able to be 
grown successfully in this experiment, but will be investigated in a later date. 
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Figure 26: k fold over WT for strains of each bacteria adapted to GEN 
An interesting observation from Figure 26 is that adaption to GEN resulted in slower 
growth for all the bacterial species tested. There are no values for S. aureus adapted 
to GEN strains because these lineages repeatedly did not meet our growth criteria. All 
cultures went into stationary phase at much lower OD values indicating that adaptation 
to GEN decreases S. aureus ability to grow to large density. 
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Figure 27: k and G fold over WT for strains of each bacteria adapted to GEN 
In A. baumannii and S. aureus there is a deviation amongst the k fold values with the 
majority of them depicting a slower growth for A. baumannii and a faster growth for S. 
aureus adapted to MEM strains. Overall, adaptation to MEM resulted in slower growth 
rates for four out of six species. The growth rate of P. aeruginosa remained at the same 
level as the WT’s. 
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Figure 28: k and G fold over WT for strains of each bacteria adapted to GEN 
A. baumannii adapted to TET grew slower than the WT strain with a deviation in the 
values for each lineage. E. cloacae and P. aeruginosa TET adapted strains had also 
a slower growth compared to the WT strains. There is a deviation also in the values 
for S. aureus with the average value showing that the adapted strains have a faster 
exponential phase than the WT strains. 
An important overall observation that we can make is that exposure of A. baumannii to 
antibiotics leads to adverse effects in its growth kinetics, as in all cases the growth rate 
k value is smaller compared to the WT’s. In addition gentamicin is a drug that slows 
down the growth of all strains. 
 
Conclusions  
The objective of this work was to observe and assess the adaptive evolution of 
ESKAPE pathogens to a suite of different classes of antibiotics and understand how 
resistance amongst those drugs is related. On this basis we performed adaptation of 
S. aureus and K. pneumoniae to cefepime and meropenem respectively, followed by 
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phenotypic characterization of all adapted ESKAPE organisms. Our results suggest 
that resistance adaptation results in cross-resistance in all species for the majority of 
the drugs investigated. Collateral sensitivity may occur, but certainly is a phenomenon 
that needs to be investigated. The strength of cross resistance or cross susceptibility 
varies for different bacteria and different drugs. In addition, adaptive evolution of K. 
pneumoniae to meropenem and S. aureus to cefepime shows that resistance 
adaptation is not a linear phenomenon, but a very complex one. In order to shed more 
light on this complexity we performed growth kinetics experiments. The results showed 
that resistance adaptation results in slowing down growth in the majority of the cases.  
However, accelerated growth was observed in S. aureus isolates adapted to five of the 
six drugs.  
Many of the observations made across the experiments cannot be understood and 
evaluated without further investigation. Sequencing of the adapted strains is necessary 
so as to understand the mechanisms leading to resistance. The data obtained here 
can be used as a compass to direct analysis of sequencing data. We expect that the 
results from the sequencing data will explain the various complex phenotypes 
observed in this work and that they may be applied to a broader range of antibiotics. 
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Appendices 
Collateral Resistance and Sensitivity Experiments – IC90 Data 
Table 14: IC90s of S. aureus adapted strains 
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Table 15: IC90s of P. aeruginosa adapted strains 
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Table 16: IC90s of K. pneumoniae adapted strains 
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Table 17: IC90s of E. faecium adapted strains 
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Table 18: IC90s of E. cloacae adapted strains 
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Table 19: IC90s of A. baumannii adapted strains 
 
 
ECOFF values 
Table 20: ECOFF values of ESKAPE pathogens to the suite of drugs used in the experiments. ND = Not Determined 
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Growth Kinetics Experiments 
Table 21: S. aureus growth kinetics data 
 
 
 
Table 22: P. aeruginosa growth kinetics data 
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Table 23: K. pneumoniae growth kinetics data 
 
 
 
Table 24: E. faecium growth kinetics data 
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Table 25: E. cloacae growth kinetics data 
 
 
 
Table 26: A. baumannii growth kinetics data 
 
